To study the link between GST genotypes, risk of cancer development, and treatment response, GSTT2B deletion, GSTT2 single-nucleotide polymorphism, and GSTT1 deletion genotypes were analysed in a cohort of healthy individuals (n = 150) and bladder cancer patients (n = 205). The gene discussed is GSTT2; the disease is cancer.